InspectIR Featured in Time Magazine

The First COVID-19 Breathalyzer Test Is Coming to the U.S.

COVID-19 testing has become more convenient and accessible, but with the pandemic still causing more than 30,000 new infections in the U.S. on average each week, having more ways to detect SARS-CoV-2 can go a long way toward eventually containing COVID-19.

On April 14, the U.S. Food and Drug Administration took an important step in that direction by authorizing the first breath-based test for the disease. The test isn’t designed to serve as a confirmed diagnosis of COVID-19, but as a screening tool to alert people who might be infected, in under three minutes. Anyone testing positive on the InspectIR system would need to confirm that result with a PCR-based test.

The test, developed by InspectIR Systems, based in Frisco, Tex., analyzes the gases in the breath and picks up the specific chemical signature of SARs-CoV-2 infection. Once infected, our cells produce a biological reaction that generates gases that are captured in the blood stream and transferred to the lungs and exhaled in the breath. Working with University of North Texas chemistry professor Guido Verbeck, InspectIR’s scientific team identified the breath print of SARS-CoV-2 by comparing the chemical profiles of breath samples from a few dozen people infected with COVID-19 and a similar number who were not. They found 41 differences that served as the basis for the test.


We are excited about the future of work…and know that InspectIR and our instrument can help alleviate some of your fears.  If you are interested in learning more, please call 469.206.4555 or write

Leave a Reply

Your email address will not be published. Required fields are marked *